Period:
Draw Mode:
| Volume | 8,849 |
|
|||||
| News | - | ||||||
| Day High | 2.77 | Low High |
|||||
| Day Low | 2.67 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Armata Pharmaceuticals Inc | ARMP | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.0394 | 1.44% | 2.77 | 13:50:48 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.73 | 2.67 | 2.77 | 2.7306 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 144 | 8,849 | $ 2.73 | $ 24,147 | - | 0.8311 - 5.2565 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:50:55 | 100 | $ 2.77 | USD |
Armata Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 100.07M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Armata Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARMP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.78 | 3.2199 | 2.5801 | 2.82 | 39,581 | -0.01 | -0.36% |
| 1 Month | 2.90 | 3.66 | 2.5801 | 3.03 | 39,495 | -0.13 | -4.48% |
| 3 Months | 1.24 | 5.2565 | 1.0701 | 2.59 | 194,193 | 1.53 | 123.39% |
| 6 Months | 1.62 | 5.2565 | 1.0701 | 2.54 | 93,525 | 1.15 | 70.99% |
| 1 Year | 4.65 | 5.2565 | 0.8311 | 2.50 | 54,914 | -1.88 | -40.43% |
| 3 Years | 3.38 | 10.48 | 0.8311 | 3.36 | 31,969 | -0.61 | -18.05% |
| 5 Years | 4.90 | 10.48 | 0.8311 | 3.74 | 41,218 | -2.13 | -43.47% |
Armata Pharmaceuticals Description
| Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing. |